Skip to main content

Profiling metalloprotease inhibition for tumour therapy

Objective

Inhibitors of metalloproteinases have shown a high therapeutic potency in preliminary clinical trials. However, unacceptable side-effects are associated, which are relative to recently discovered ADAMS and "non classical" effects of MMPs. This project aims at defining the best MMP inhibition profiles for cancer therapy by
1) a comprehensive assessment of metalloprateinase activities and functions at both physiological and tumour progression level, i.e. by using first inhibition inhibitors as probe;
2) designing new metalloproteinase inhibitors on the basis of inhibitor-enzyme complex 3-D structures and on the biological activities to be tackled;
3) assessing the benefit of combining MMP inhibitors with serine proteases inhibitors designed on a similar basis.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

UNIVERSITE DE LIEGE*ULG
Address
Place Du 20 Aout 7
4000 Liege
Belgium

Participants (9)

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
France
Address
Rue Laurent Fries 1
67404 Illkirch Graffenstaden
COMMISSARIAT A L'ENERGIE ATOMIQUE
France
Address
Batiment 152, Cea/saclay
91191 Gif Sur Yvette
COPENHAGEN UNIVERSITY HOSPITAL
Denmark
Address
Stransboulevarden 49
2100 Koepenhagen
GERMAN CANCER RESEARCH CENTER
Germany
Address
Im Neuenheimer Feld 280
69120 Heidelberg
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
Address
Rue Laurent Fries 1
67404 Illkirch Graffenstaden
MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
Germany
Address
Am Klopferspitz 18 A
82152 Martinsried
NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS
Greece
Address
Panepistimiopolis Zographou
15771 Zographos, Athens
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
United Kingdom
Address
Trinity Lane, The Old Schools,
CB2 1TN Cambridge
UNIVERSIDAD DE OVIEDO
Spain
Address
San Francisco 1-5
33003 Oviedo